229957-07-7

Basic information

• Product Name: 3,4-DIFLUOROBENZOIC ACID HYDRAZIDE
• Synonyms: 3,4-DIFLUOROBENZENE-1-CARBOHYDRAZIDE;3,4-DIFLUOROBENZHYDRAZIDE;3,4-DIFLUOROBENZOIC ACID HYDRAZIDE;3,4-DIFLUOROBENZOIC HYDRAZIDE
• CAS NO: 229957-07-7
• Molecular Formula: C₇H₆F₂N₂O
• Molecular Weight: 172.13
• Product Categories: Fluorine Compounds
• Mol File: 229957-07-7.mol

Chemical Properties

• Melting Point: 143-145°C
• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.372g/cm³
• Refractive Index: 1.53
• CAS DataBase Reference: 3,4-DIFLUOROBENZOIC ACID HYDRAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-DIFLUOROBENZOIC ACID HYDRAZIDE(229957-07-7)
• EPA Substance Registry System: 3,4-DIFLUOROBENZOIC ACID HYDRAZIDE(229957-07-7)

Safety Data

• Hazard Codes: Xi
• Statements: 20/21/22
• Safety Statements: 22-36/37/39
• Hazardous Substances Data: 229957-07-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3,4-Difluorobenzoic acid hydrazide is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with improved properties. Its unique structure allows for the creation of molecules with enhanced biological activity and selectivity.
Used in Agrochemical Industry:
In the agrochemical sector, 3,4-difluorobenzoic acid hydrazide is utilized as a precursor in the production of agrochemicals, such as pesticides and herbicides. Its incorporation into these compounds can lead to more effective and targeted pest control, benefiting agricultural productivity and crop protection.
Used in Organic Synthesis:
3,4-Difluorobenzoic acid hydrazide is employed as a versatile building block in organic synthesis for the preparation of a range of biologically active compounds. Its unique structural features facilitate the creation of diverse chemical entities with potential applications in medicine, materials science, and other fields.

InChI:InChI=1/C7H6F2N2O/c8-5-2-1-4(3-6(5)9)7(12)11-10/h1-3H,10H2,(H,11,12)

Upstream product

• 76903-88-3 3,4-difluorobenzoyl chloride 
• 455-86-7 3,4-Difluorobenzoic acid 
• 369-25-5 methyl 3,4-difluorobenzoate 

Downstream Products

• 1093391-00-4 C₈H₄F₂N₂OS 
• 1445205-21-9 2-butoxy-5-(5-(5-(3,4-difluorophenyl)-4H-1,2,4-triazol-3-yl)pyridin-2-yl)pyrimidine 
• 1445207-05-5 2-bromo-5-(5-(3,4-difluorophenyl)-4H-1,2,4-triazol-3-yl)pyridine 
• 1456613-89-0 2-(3,4-difluorophenyl)-5-thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one 
• 1456614-11-1 C₁₂H₁₁F₂N₅O₂S 
• 1016715-11-9 C₈H₆F₂N₄ 
• 1182368-02-0 N'-((2R,3R)-2-(3-chloro-4-cyano-2-methylphenylamino)-3-hydroxybutanoyl)-3,4-difluorobenzohydrazide 
• 1021939-00-3 4-[N'-(3,4-difluorobenzoyl)hydrazino]-4-oxobutyric acid ethyl ester 

Relevant articles and documents

AMINO ALCOHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF

The present invention belongs to the field of medicine, and specifically discloses an amino alcohol derivative represented by Formula I, a pharmaceutically acceptable salt, solvate, polymorph or prodrug thereof. In addition, the present invention also discloses a pharmaceutical composition comprising the above substances, and a use of the substance in the preparation of a medicament for the prevention and treatment of an immune inflammatory disease, or a disease or condition associated with immunological competence such as multiple sclerosis, ALS, CIDP, systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, psoriasis, polymyositis, etc.

OXADIAZINONE COMPOUNDS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES

The present invention includes name compounds of general formula (I) in which R1, Y, and R3 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compos

Inhibition of tobacco bacterial wilt with sulfone derivatives containing an 1,3,4-oxadiazole moiety

A series of new sulfone compounds containing the 1,3,4-oxadiazole moiety were designed and synthesized. Their structures were identified by 1H and 13C nuclear magnetic resonance and elemental analyses. Antibacterial bioassays indicated that most compounds exhibited promising in vitro antibacterial bioactivities against tobacco bacterial wilt at 200 μg/mL. The relationship between structure and antibacterial activity was also discussed. Among the title compounds, 5′c, 5′h, 5′i, and 5′j could inhibit mycelia growth of Ralstonia solanacearum in vitro by approximately 50% (EC50) at 39.8, 60.3, 47.9, and 32.1 μg/mL, respectively. Among them, compound 5′j was identified as the most promising candidate due to its stronger effect than that of Kocide 3000 [Cu(OH)2] within the same concentration range. Field trials demonstrated that the control effect of compound 5′j against tobacco bacterial wilt was better than that of the commercial bactericide Saisentong. For the first time, the present work demonstrated that sulfone derivatives containing 1,3,4-oxadiazole can be used to develop potential bactericides for plants.

Antileishmanial activity screening of 5-nitro-2-heterocyclic benzylidene hydrazides

A series of 53 nitro derivatives rationally designed were obtained by parallel synthesis and screened against Leishmania donovani. Six compounds exhibited IC50 values lower than standard drugs. Brief SAR analysis revealed that substitution is important to the activity. Nitrothiophene analogues were more potent than the nitrofuran ones. This was attributed to the ability of sulfur atoms in accommodating electrons from nitro group, which facilitate its reduction and therefore the formation of free radicals lethal to parasites.